Hairy cell leukemia: Evaluation of the long-term outcome in 121 patients

Cancer

Volumn 116, Issue 20, 2010, Pages 4788-4792

  Zinzani, Pier Luigi ^a   Pellegrini, Cinzia ^a   Stefoni, Vittorio ^a   Derenzini, Enrico ^a   Gandolfi, Letizia ^a   Broccoli, Alessandro ^a   Argnani, Lisa ^a   Quirini, Federica ^a   Pileri, Stefano ^a   Baccarani, Michele ^a  

^a Hematology Institute L e a Semgnoli   (Italy)

Author keywords

Alpha interferon; Cladribine; Hairy cell leukemia; Pentostatin; Rituximab; Splenectomy

Indexed keywords

ALPHA INTERFERON; CLADRIBINE; COTRIMOXAZOLE; PENTOSTATIN; RITUXIMAB; 2 CHLORO 3' DEOXYADENOSINE; 2 CHLOROADENOSINE; 2-CHLORO-3'-DEOXYADENOSINE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYADENOSINE DERIVATIVE; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; CONTINUOUS INFUSION; FEMALE; FOLLOW UP; HAIRY CELL LEUKEMIA; HIGH RISK POPULATION; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RETREATMENT; RETROSPECTIVE STUDY; SPLENECTOMY; TREATMENT DURATION; TREATMENT RESPONSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; MIDDLE AGED; TREATMENT OUTCOME;

2-CHLOROADENOSINE; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYADENOSINES; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, HAIRY CELL; MALE; MIDDLE AGED; RETREATMENT; SPLENECTOMY; TREATMENT OUTCOME;

EID: 78349281132     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25243     Document Type: Article

References (28)

1. Berman E, Heller G, Kempin S, Gee T, Tran LL, Clarkson B. Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a. Blood. 1990;75:839-845. (Pubitemid 20067180)
2. Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol. 1995;13:974-982.
3. Federico M, Frassoldati A, Lamparelli T, et al. Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCL. Ann Oncol. 1994;5:725-731. (Pubitemid 24302689)
4. Flandrin G, Sigaux F, Sebahoun G, Bouffette P. Hairy cell leukemia: clinical presentation and follow-up of 211 patients. Semin Oncol. 1984;11:458-471. (Pubitemid 15150319)
5. Spiers AS, Moore D, Cassileth PA, et al. Remissions in hairy-cell leukemia with pentostatin (20-deoxycoformycin). N Engl J Med. 1987;316:825-830. (Pubitemid 17056319)
6. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med. 1990;322:1117-1121. (Pubitemid 20149529)
7. Dearden CE, Matutes E, Hilditch BL, Swansbury GJ, Catovsky D. Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin for cladribine. Br J Haematol. 1999;106:515-519. (Pubitemid 29450680)
8. Chadha P, Rademaker AW, Mendiratta P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood. 2005;106:241-246. (Pubitemid 40967199)
9. Maloisel F, Benboubker L, Gardembas M, et al. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia. 2003;17:45-51. (Pubitemid 36175887)
10. Rafel M, Cervantes F, Beltran JM, et al. Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients. Cancer. 2000;88:352-357. (Pubitemid 30051819)
11. Zinzani PL, Tani M, Marchi E, et al. Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica. 2004;89:309-313. (Pubitemid 38788415)
12. Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood. 2000;96:2981-2986.
13. Jehn U, Bartl R, Dietzfelbinger H, Haferlach T, Heinemann V. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia. 2004;18:1476-1481. (Pubitemid 39264069)
14. Else M, Ruchlemer R, Osuji N, et al. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer. 2005;104:2442-2448. (Pubitemid 41691566)
15. Filleul B, Delannoy A, Ferrant A, et al. A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia. 1994;8:1153-1156. (Pubitemid 24224518)
16. Else M, Dearden CE, Matutes E, et al. Long-term followup of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009;145:733-740.
17. Consensus resolution: proposed criteria for evaluation of response to treatment in hairy cell leukemia. Leukemia. 1987;1:405.
18. Saven A, Burian C, Koziol JA, Piro LD. Long-term followup of patients with hairy cell leukemia after cladribine treatment. Blood. 1998;92:1918-1926. (Pubitemid 28446680)
19. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003;21:891-896. (Pubitemid 46606450)
20. Tallman MS, Hakinian D, Rademaker AW, et al. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: longterm follow-up of the Northwestern University experience. Blood. 1996;88:1954-1959. (Pubitemid 26307896)
21. Zinzani PL, Ascani S, Piccaluga PP, et al. Efficacy of rituximab in hairy cell leukemia treatment. J Clin Oncol. 2000;18:3875-3877.
22. Lauria F, Lenoci M, Annino L, et al. Efficacy of anti-CD20 monoclonal antibodies (MabThera) in patients with progressed hairy cell leukemia. Haematologica. 2001;86:1046-1050. (Pubitemid 33031870)
23. Nieva J, Betel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood. 2003;102:810-813. (Pubitemid 36917768)
24. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001;345:241-247. (Pubitemid 32695063)
25. Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol. 2005;23:6719-6729. (Pubitemid 46190267)
26. Else M, Osuji N, Forconi F, et al. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. Cancer. 2007;110:2240-2247. (Pubitemid 350100746)
27. Ravandi F, Jorgensen JF, O'Brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood. 2006;107:4658-4662. (Pubitemid 43882611)
28. Cervetti G, Galimberti S, Andreazzoli F, et al. Rituximab as treatment for minimal residual disease in hairy cell leukemia: extended follow-up. Br J Haematol. 2008;143:296-298.